Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julia Chisholm

Showing results (11-20 of 48) with videos related to

Pageof 5
Sort By:
Pediatric Blood & Cancer|December 31, 2016
Impact of fusion gene status versus histology on risk-stratification for rhabdomyosarcoma: Retrospective analyses of patients on UK trialsJoanna Selfe, David Olmos, Reem Al-Saadi, et al.
Pediatric Blood & Cancer|May 6, 2009
Infection-related mortality in children with malignancy in England and Wales, 2003-2005Jessica Bate, Shamez Ladhani, Mike Sharland, et al.
Haematologica|March 16, 2012
Variations in non-pharmacological anti-infective measures in childhood leukemia--results of an international surveyThomas Lehrnbecher, Richard Aplenc, Fernanda Rivas Pereira, et al.
Cancer Chemotherapy and Pharmacology|February 15, 2016
Adaptive dosing of anticancer drugs in neonates: facilitating evidence-based dosing regimensGareth J Veal, Julie Errington, Jairam Sastry, et al.
BMJ Open|January 10, 2015
An emerging evidence base for PET-CT in the management of childhood rhabdomyosarcoma: systematic reviewGill Norman, Debra Fayter, Kate Lewis-Light, et al.
Archives of Disease in Childhood|July 1, 2011
PEPtalk: postexposure prophylaxis against varicella in children with cancerJessica Bate, Julia Chisholm, Paul T Heath, et al.
Cancers|August 12, 2023
Maintenance Chemotherapy for Patients with RhabdomyosarcomaGianni Bisogno, Veronique Minard-Colin, Meriel Jenney, et al.
International Journal of Cancer|December 10, 2023
A systematic review of early phase studies for children and young people with relapsed and refractory rhabdomyosarcoma: The REFoRMS-SR projectConnor Evans, Lucy Shepherd, Gemma Bryan, et al.
Pediatric Blood & Cancer|November 21, 2024
Implications of Implementing Children's Oncology Group Risk Stratification to Patients With Rhabdomyosarcoma Treated on European Paediatric Soft Tissue Sarcoma Study Group Clinical TrialGianni Bisogno, Veronique Minard-Colin, Josephine Haduong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2012
PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratificationEdoardo Missiaglia, Dan Williamson, Julia Chisholm, et al.
Pageof 5

Showing results (11-20 of 48) with videos related to

Sort By:
Pageof 5
Pediatric Blood & Cancer|December 31, 2016
Impact of fusion gene status versus histology on risk-stratification for rhabdomyosarcoma: Retrospective analyses of patients on UK trialsJoanna Selfe, David Olmos, Reem Al-Saadi, et al.
Pediatric Blood & Cancer|May 6, 2009
Infection-related mortality in children with malignancy in England and Wales, 2003-2005Jessica Bate, Shamez Ladhani, Mike Sharland, et al.
Haematologica|March 16, 2012
Variations in non-pharmacological anti-infective measures in childhood leukemia--results of an international surveyThomas Lehrnbecher, Richard Aplenc, Fernanda Rivas Pereira, et al.
Cancer Chemotherapy and Pharmacology|February 15, 2016
Adaptive dosing of anticancer drugs in neonates: facilitating evidence-based dosing regimensGareth J Veal, Julie Errington, Jairam Sastry, et al.
BMJ Open|January 10, 2015
An emerging evidence base for PET-CT in the management of childhood rhabdomyosarcoma: systematic reviewGill Norman, Debra Fayter, Kate Lewis-Light, et al.
Archives of Disease in Childhood|July 1, 2011
PEPtalk: postexposure prophylaxis against varicella in children with cancerJessica Bate, Julia Chisholm, Paul T Heath, et al.
Cancers|August 12, 2023
Maintenance Chemotherapy for Patients with RhabdomyosarcomaGianni Bisogno, Veronique Minard-Colin, Meriel Jenney, et al.
International Journal of Cancer|December 10, 2023
A systematic review of early phase studies for children and young people with relapsed and refractory rhabdomyosarcoma: The REFoRMS-SR projectConnor Evans, Lucy Shepherd, Gemma Bryan, et al.
Pediatric Blood & Cancer|November 21, 2024
Implications of Implementing Children's Oncology Group Risk Stratification to Patients With Rhabdomyosarcoma Treated on European Paediatric Soft Tissue Sarcoma Study Group Clinical TrialGianni Bisogno, Veronique Minard-Colin, Josephine Haduong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2012
PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratificationEdoardo Missiaglia, Dan Williamson, Julia Chisholm, et al.
Pageof 5